Jefferies Starts Zynerba Pharmaceuticals (ZYNE) at Buy

Jefferies initiates coverage on Zynerba Pharmaceuticals (NASDAQ: ZYNE) with a Buy rating and a price target of $33.00.

Analyst Biren Amin commented, "ZYNE is poised to become a leader in synthetic cannabinoid therapies with a focus on transdermal delivery. Its lead candidate is ZYN002, a permeation-enhanced CBD gel delivered through a transdermal patch for refractory epilepsy. Delivering CBD through the skin could lead to an improved safety profile over oral formulations. ZYNE is set to begin a PI trial in H2'15."

For an analyst ratings summary and ratings history on Zynerba Pharmaceuticals click here. For more ratings news on Zynerba Pharmaceuticals click here.

Shares of Zynerba Pharmaceuticals closed at $27.40 yesterday.

You May Also Be Interested In

• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
• KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating